Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Prevalence of smoking in adults with cystic fibrosis
研究概览
简要总结
In the collective unconscious, a patient with cystic fibrosis does not smoke. This belief is so deeply rooted that there is virtually no French data on the prevalence of smoking among this vulnerable population.
Faced with a cohort of patients undergoing a complete transformation (improved quality of life and life expectancy, fewer hospitalizations, reduced respiratory symptoms, better social integration), it is becoming urgent to assess the current situation in order to optimize tobacco prevention.
This is all the more important given the emergence of international studies objectively examining the interactions between smoking, vaping, and the efficacy of Kaftrio.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patient (≥ 18 years old)
- •With confirmed cystic fibrosis
- •Regular follow-up at the Strasbourg Adult Cystic Fibrosis Center
排除标准
- •Patients who have undergone a double lung transplant for cystic fibrosis.
结局指标
主要结局
Prevalence of smoking in adults with cystic fibrosis
时间窗: Up to 12 months
The proportion of adults with cystic fibrosis who smoke: Example: If 10 out of 100 adults with cystic fibrosis smoke, then the prevalence of smoking in this group is 10%.
次要结局
未报告次要终点